Search Results
Clinical Trials
Expanded Access of Kv7.2 Channel Activators
Kv7.2 Channel Activators In many cases, KCNQ2-DEE is caused by reduced Kv7.2 potassium channel activity. Because of this, therapeutics that boost the activity of these channels are likely to be an effective treatment approach. Support for this comes from research showing that a Kv7.2 channel opener, retigabine (also called ezogabine), reduced seizures and improved alertness,…
Praxis EMERALD Clinical Trial
KCNQ2 Cure hosted a webinar for the KCNQ2 community featuring a discussion with Praxis Precision Medicines. Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for disorders of the central nervous system characterized by an imbalance between neuronal excitation and inhibition, a mechanism that is highly relevant to many developmental and epileptic…
Promising Results from EMBOLD Study: What this Means for the KCNQ2 Community
KCNQ2 Cure Alliance attended the American Epilepsy Society (AES) meeting this week. One of the biggest pieces of news shared was positive results from a clinical trial testing a new anti-seizure medication in individuals with developmental epileptic encephalopathy. Read more below on what this means for our KCNQ2 community and stay tuned for more AES…
KCNQ2-DEE Clinical Trial
Xenon Pharmaceuticals is currently developing XEN496, which is a proprietary pediatric formulation of the active ingredient ezogabine, for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE). Ezogabine was previously approved by the U.S. Food and Drug Administration (FDA), as an anti-epileptic drug as an adjunctive treatment for adults with focal seizures with or without…